NO329690B1 - Tablett med hoy dose av ibandronat-formulering samt fremgangsmate for fremstilling av slike - Google Patents
Tablett med hoy dose av ibandronat-formulering samt fremgangsmate for fremstilling av slike Download PDFInfo
- Publication number
- NO329690B1 NO329690B1 NO20044722A NO20044722A NO329690B1 NO 329690 B1 NO329690 B1 NO 329690B1 NO 20044722 A NO20044722 A NO 20044722A NO 20044722 A NO20044722 A NO 20044722A NO 329690 B1 NO329690 B1 NO 329690B1
- Authority
- NO
- Norway
- Prior art keywords
- weight
- tablet
- active substance
- polyvinylpyrrolidone
- physiologically safe
- Prior art date
Links
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 title claims description 24
- 238000002360 preparation method Methods 0.000 title abstract description 15
- 238000000034 method Methods 0.000 title abstract description 5
- 239000000203 mixture Substances 0.000 title description 20
- 229940015872 ibandronate Drugs 0.000 title description 10
- 238000009472 formulation Methods 0.000 title 1
- 239000013543 active substance Substances 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 16
- 229960005236 ibandronic acid Drugs 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000000945 filler Substances 0.000 claims description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000007884 disintegrant Substances 0.000 claims description 8
- 235000021355 Stearic acid Nutrition 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
- 239000008117 stearic acid Substances 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000008119 colloidal silica Substances 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000000835 fiber Substances 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 abstract description 11
- 150000004663 bisphosphonates Chemical class 0.000 abstract description 11
- 239000003826 tablet Substances 0.000 description 17
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 239000007888 film coating Substances 0.000 description 6
- 238000009501 film coating Methods 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 229960000913 crospovidone Drugs 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- PMXAPNNYCFBALB-UHFFFAOYSA-N (1-hydroxy-1-phosphono-3-pyrrolidin-1-ylpropyl)phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCN1CCCC1 PMXAPNNYCFBALB-UHFFFAOYSA-N 0.000 description 3
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 3
- 229920003080 Povidone K 25 Polymers 0.000 description 3
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 3
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229960003943 hypromellose Drugs 0.000 description 3
- 229960001021 lactose monohydrate Drugs 0.000 description 3
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 3
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 3
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 3
- 229940100487 povidone k25 Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 3
- 229920003084 Avicel® PH-102 Polymers 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- -1 Pharmacoat®) Chemical compound 0.000 description 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 2
- 229940062527 alendronate Drugs 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229960002286 clodronic acid Drugs 0.000 description 2
- ZZFKAZHZSSJSSE-UHFFFAOYSA-L disodium;[(cycloheptylamino)-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate;hydrate Chemical compound O.[Na+].[Na+].OP(O)(=O)C(P([O-])([O-])=O)NC1CCCCCC1 ZZFKAZHZSSJSSE-UHFFFAOYSA-L 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940009626 etidronate Drugs 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229950006971 incadronic acid Drugs 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229950010733 neridronic acid Drugs 0.000 description 2
- 229940046231 pamidronate Drugs 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229940089617 risedronate Drugs 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 229940019375 tiludronate Drugs 0.000 description 2
- 229960004276 zoledronic acid Drugs 0.000 description 2
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MSRAKLIASXPRRV-UHFFFAOYSA-N OC(C(C1=CC=CN=C1)OP(O)=O)OP(O)=O Chemical compound OC(C(C1=CC=CN=C1)OP(O)=O)OP(O)=O MSRAKLIASXPRRV-UHFFFAOYSA-N 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02028745 | 2002-12-20 | ||
| PCT/EP2003/008732 WO2004056373A1 (en) | 2002-12-20 | 2003-08-07 | High dose ibandronate formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20044722L NO20044722L (no) | 2004-11-01 |
| NO329690B1 true NO329690B1 (no) | 2010-11-29 |
Family
ID=32524013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20044722A NO329690B1 (no) | 2002-12-20 | 2004-11-01 | Tablett med hoy dose av ibandronat-formulering samt fremgangsmate for fremstilling av slike |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US7923028B2 (pl) |
| EP (2) | EP1596870B2 (pl) |
| JP (1) | JP4427453B2 (pl) |
| KR (1) | KR100694550B1 (pl) |
| CN (1) | CN1649598B (pl) |
| AR (2) | AR037560A1 (pl) |
| AT (1) | ATE369139T1 (pl) |
| AU (1) | AU2003250218B2 (pl) |
| BR (1) | BR0309691A (pl) |
| CA (1) | CA2484494C (pl) |
| CR (1) | CR7549A (pl) |
| CY (2) | CY1107757T1 (pl) |
| DE (1) | DE60315514T3 (pl) |
| DK (2) | DK1596870T4 (pl) |
| EC (1) | ECSP045418A (pl) |
| EG (1) | EG26027A (pl) |
| ES (2) | ES2530791T3 (pl) |
| HK (1) | HK1080714A1 (pl) |
| HR (1) | HRP20041013B1 (pl) |
| IL (2) | IL164956A (pl) |
| JO (1) | JO2663B1 (pl) |
| MX (1) | MXPA04010866A (pl) |
| MY (1) | MY143550A (pl) |
| NO (1) | NO329690B1 (pl) |
| NZ (2) | NZ536273A (pl) |
| PA (1) | PA8580601A1 (pl) |
| PE (1) | PE20040416A1 (pl) |
| PL (1) | PL212072B1 (pl) |
| PT (2) | PT1790347E (pl) |
| RU (1) | RU2315603C2 (pl) |
| SG (1) | SG174628A1 (pl) |
| SI (2) | SI1790347T1 (pl) |
| TW (1) | TWI342215B (pl) |
| UY (1) | UY27942A1 (pl) |
| WO (1) | WO2004056373A1 (pl) |
| ZA (1) | ZA200408822B (pl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100642961B1 (ko) | 2002-05-10 | 2006-11-10 | 에프. 호프만-라 로슈 아게 | 골다공증 치료 및 예방용 비스포스폰산 |
| KR20060100395A (ko) * | 2003-09-29 | 2006-09-20 | 씨아이피엘에이 엘티디. | 안정성이 개선된 약제학적 제제 |
| JP4559431B2 (ja) * | 2004-08-23 | 2010-10-06 | テバ ファーマシューティカル インダストリーズ リミティド | 固体及び結晶イバンドロネートナトリウム及びその調製方法 |
| LT2662380T (lt) * | 2005-02-01 | 2019-03-12 | Atnahs Pharma Uk Limited | Ibandronato polimorfo a medicininis panaudojimas |
| US20070191315A1 (en) * | 2006-02-16 | 2007-08-16 | Bengt Bergstrom | Method for administering ibandronate |
| DE102006012866B4 (de) | 2006-03-19 | 2009-04-09 | Uic Gmbh | Verfahren zur Abtrennung leichtflüchtiger Komponenten aus einem Stoffgemisch sowie Vorrichtung zur Durchführung dieses Verfahrens |
| GB0616794D0 (en) * | 2006-08-24 | 2006-10-04 | Arrow Int Ltd | Solid dosage form |
| WO2008026907A1 (es) * | 2006-08-29 | 2008-03-06 | Espinosa Abdala Leopoldo De Je | Composición farmacéutica que comprende ibandronato y vitamina d3 para el tratamiento de osteoporosis |
| US20080139514A1 (en) * | 2006-11-29 | 2008-06-12 | Subhash Pandurang Gore | Diphosphonic acid pharmaceutical compositions |
| WO2009018834A1 (en) * | 2007-08-06 | 2009-02-12 | Pharmathen S.A. | Pharmaceutical composition containing bisphosphonate and method for the preparation thereof |
| KR20100014090A (ko) * | 2008-08-01 | 2010-02-10 | 동화약품주식회사 | 벤즈아미딘 유도체 또는 이의 염, 및 비스포스포네이트를 포함하는 골다공증의 예방 또는 치료용 약학 조성물 |
| NO2459176T3 (pl) | 2009-07-31 | 2018-02-24 | ||
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| CN102000094B (zh) * | 2010-09-27 | 2013-03-27 | 天津南开允公医药科技有限公司 | 一种含有伊班膦酸的药物组合物及制备工艺 |
| KR101244414B1 (ko) * | 2010-11-05 | 2013-03-18 | 주식회사 바이오파마티스 | 고함량 이반드론산 함유 골다공증 예방 또는 치료용 조성물 및 이의 제조방법 |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| WO2012093974A1 (en) | 2011-01-06 | 2012-07-12 | Mahmut Bilgic | Improved bisphosphonate formulations |
| US9854831B2 (en) * | 2012-01-20 | 2018-01-02 | Altria Client Services Llc | Oral product |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US118634A (en) * | 1871-08-29 | Improvement in attachments of band-cutters and thrashing-machines | ||
| US97469A (en) * | 1869-11-30 | Improved compound for disinfecting- and deodorizing | ||
| US175884A (en) * | 1876-04-11 | Improvement in galvanic batteries | ||
| US139378A (en) * | 1873-05-27 | Improvement in folding-guides for sewing-machines | ||
| US147484A (en) * | 1874-02-17 | Improvement in shirt-bosom supporters | ||
| US195171A (en) * | 1877-09-11 | Improvement in jacks for vehicles | ||
| US87550A (en) * | 1869-03-09 | Improvement in direct-acting steam-engines | ||
| DE1248654B (de) | 1964-11-11 | 1967-08-31 | Albright & Wilson (Mf g) Limited, Oldbury, Warwickshire (Großbritannien) | Verfahren zur Herstellung von Phosphonsäuren und deren Salzen |
| DE1251759B (de) | 1965-03-30 | 1967-10-12 | The Procter S. Gamble Company, Cincinnati, Ohio (V St A) | Verfahren zur kontinuierlichen Herstellung von Athan 1 hydroxy - 1 1-diphosphonsaure |
| US3475486A (en) | 1966-09-12 | 1969-10-28 | Monsanto Co | Process for preparing phosphonic acids |
| US4134969A (en) | 1974-02-04 | 1979-01-16 | Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa) | Method of treatment of calcium disorders using aminoalkane-diphosphonic acids |
| DE2405254C2 (de) | 1974-02-04 | 1982-05-27 | Henkel KGaA, 4000 Düsseldorf | Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper |
| US4073838A (en) | 1974-08-12 | 1978-02-14 | Boehringer Ingelheim Gmbh | Granulating process |
| DE2534391C2 (de) | 1975-08-01 | 1983-01-13 | Henkel KGaA, 4000 Düsseldorf | 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren |
| DE2745083C2 (de) | 1977-10-07 | 1985-05-02 | Henkel KGaA, 4000 Düsseldorf | Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung |
| DE2943498C2 (de) | 1979-10-27 | 1983-01-27 | Henkel KGaA, 4000 Düsseldorf | Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure |
| DE3016289A1 (de) | 1980-04-28 | 1981-10-29 | Henkel KGaA, 4000 Düsseldorf | Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren |
| BE885139A (fr) | 1981-03-09 | 1981-03-09 | Vs Chemicko Technologicka Prah | Acide 6-amino-1-hydroxyhexylidene-disphosphonique, sels de cet acide et procede de fabrication de ces produits |
| CH658009A5 (de) | 1982-02-12 | 1986-10-15 | Concast Service Union Ag | Verfahren und plattenkokille zum kuehlen und stuetzen eines stranges in einer plattenkokille einer stahlstranggiessanlage. |
| IT1201087B (it) | 1982-04-15 | 1989-01-27 | Gentili Ist Spa | Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| FR2531088B1 (fr) | 1982-07-29 | 1987-08-28 | Sanofi Sa | Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation |
| IT1195993B (it) | 1984-01-12 | 1988-11-03 | Gentili Ist Spa | Forme farmaceutiche a base di difosfonati |
| US4639338A (en) | 1984-08-06 | 1987-01-27 | Ciba-Geigy Corporation | Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate |
| DE3434667A1 (de) | 1984-09-21 | 1986-04-03 | Henkel KGaA, 4000 Düsseldorf | 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung |
| IT1196315B (it) | 1984-10-29 | 1988-11-16 | Gentili Ist Spa | Procedimento per la preparazione di acidi difosfonici |
| US4812311A (en) | 1984-12-21 | 1989-03-14 | The Procter & Gamble Company | Kit for use in the treatment of osteoporosis |
| DE3512536A1 (de) | 1985-04-06 | 1986-10-16 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| US4761406A (en) | 1985-06-06 | 1988-08-02 | The Procter & Gamble Company | Regimen for treating osteoporosis |
| DE3540150A1 (de) | 1985-11-13 | 1987-05-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| DE3623397A1 (de) | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| DE3626058A1 (de) | 1986-08-01 | 1988-02-11 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| IL84497A (en) | 1986-11-21 | 1994-10-21 | Ciba Geigy Ag | History 2-) Imidazol-1-yl (ethane-1,1-diphosphonic acid, their preparation and pharmaceutical preparations containing them |
| DE3640938A1 (de) | 1986-11-29 | 1988-06-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel |
| CA1339805C (en) | 1988-01-20 | 1998-04-07 | Yasuo Isomura | (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active |
| US5030447A (en) | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
| GB8808138D0 (en) | 1988-04-07 | 1988-05-11 | Leo Pharm Prod Ltd | Chemical compounds |
| FR2629716B1 (fr) | 1988-04-07 | 1991-07-19 | Sanofi Sa | Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique |
| DE3822650A1 (de) | 1988-07-05 | 1990-02-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| US4958839A (en) | 1988-07-12 | 1990-09-25 | Guzik Technical Enterprises, Inc. | Disc clamp employing resilient cone for spreading balls |
| US4990503A (en) | 1988-08-12 | 1991-02-05 | Yamanouchi Pharmaceutical Co., Ltd. | Heterocyclic bisphosphonic acid derivatives |
| US5018651A (en) | 1988-12-27 | 1991-05-28 | Hull Harold L | Side or end dump article carrier |
| DE3917153A1 (de) | 1989-05-26 | 1990-11-29 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| US4922007A (en) | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
| US5356887A (en) | 1990-01-31 | 1994-10-18 | Merck & Co., Inc. | Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids |
| US5019651A (en) | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
| US5203253A (en) * | 1990-10-09 | 1993-04-20 | Ore-Ida Foods, Inc. | Automatic air cooking system for vending machines |
| US5262173A (en) | 1992-03-02 | 1993-11-16 | American Cyanamid Company | Pulsatile once-a-day delivery systems for minocycline |
| TW237386B (pl) | 1992-04-15 | 1995-01-01 | Ciba Geigy | |
| US5358941A (en) | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
| FR2703590B1 (fr) | 1993-04-05 | 1995-06-30 | Sanofi Elf | Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse . |
| US5431920A (en) | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
| TW390813B (en) † | 1994-04-29 | 2000-05-21 | Merck & Co Inc | Wet granulation formulation for bisphosphonic acids |
| US20010007863A1 (en) | 1998-06-18 | 2001-07-12 | Merck & Co., Inc. | Wet granulation formulation for bisphosphonic acids |
| US5462932A (en) | 1994-05-17 | 1995-10-31 | Merck & Co., Inc. | Oral liquid alendronate formulations |
| CZ289081B6 (cs) | 1994-09-22 | 2001-10-17 | Akzo Nobel N. V. | Způsob výroby farmaceutické lékové formy a tableta |
| FR2727629A1 (fr) * | 1994-12-06 | 1996-06-07 | Sanofi Sa | Trousse pour cycle de traitement de l'osteoporose |
| US20010051616A1 (en) | 1995-02-17 | 2001-12-13 | David B. Karpf | Method of lessening the risk of vertebral fractures |
| US6123964A (en) * | 1995-10-27 | 2000-09-26 | Merck & Co., Inc. | Wet granulation formulation of a growth hormone secretagogue |
| AU7522896A (en) † | 1995-10-27 | 1997-05-15 | Merck & Co., Inc. | Wet granulation formulation of a growth hormone secretagogue |
| CN1222079A (zh) * | 1996-04-20 | 1999-07-07 | 曼海姆泊灵格股份公司 | 含有伊波膦酸盐的口服药物制剂 |
| DE19615812A1 (de) | 1996-04-20 | 1997-10-23 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation |
| US6905701B2 (en) | 1997-06-11 | 2005-06-14 | Umd, Inc. | Formulations for transmucosal vaginal delivery of bisphosphonates |
| WO1998056360A2 (en) | 1997-06-11 | 1998-12-17 | The Procter & Gamble Company | Film-coated tablet for improved upper gastrointestinal tract safety |
| US5994329A (en) | 1997-07-22 | 1999-11-30 | Merck & Co., Inc. | Method for inhibiting bone resorption |
| US6432932B1 (en) | 1997-07-22 | 2002-08-13 | Merck & Co., Inc. | Method for inhibiting bone resorption |
| IL121623A (en) | 1997-08-26 | 2000-06-29 | Unipharm Ltd | Process for the preparation of solid oral dosage forms comprising alendronic acid |
| US6124314A (en) * | 1997-10-10 | 2000-09-26 | Pfizer Inc. | Osteoporosis compounds |
| US6432931B1 (en) | 1998-06-24 | 2002-08-13 | Merck & Co., Inc. | Compositions and methods for inhibiting bone resorption |
| IT1303672B1 (it) | 1998-07-28 | 2001-02-23 | Nicox Sa | Sali nitrati di farmaci attivi nei disordini ossei |
| GB9816899D0 (en) * | 1998-08-05 | 1998-09-30 | Boots Co Plc | Therapeutic agents |
| EP0998932A1 (de) † | 1998-10-09 | 2000-05-10 | Boehringer Mannheim Gmbh | Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung |
| EP0998933A1 (de) | 1998-10-09 | 2000-05-10 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation |
| DE19846687C2 (de) | 1998-10-09 | 2001-07-26 | Auer Dorothee | Chirurgische Hilfsvorrichtung zur Verwendung beim Ausführen von medizinischen Eingriffen und Verfahren zum Erzeugen eines Bildes im Rahmen von medizinischen Eingriffen |
| JP3793023B2 (ja) | 1998-12-04 | 2006-07-05 | ロシュ ダイアグノスティックス ゲーエムベーハー | 体内プロテーゼの骨統合を促進するためのイバンドロネートの使用 |
| SE9901272D0 (sv) | 1999-04-09 | 1999-04-09 | Astra Ab | New improved formulation |
| CA2308532C (en) | 1999-05-12 | 2005-11-29 | Gador S.A. | Use of bisphosphonates for the treatment of osteogenesis imperfecta |
| AR024462A1 (es) | 1999-07-01 | 2002-10-02 | Merck & Co Inc | Tabletas farmaceuticas |
| FR2797185B1 (fr) * | 1999-08-06 | 2001-10-26 | Galenix Dev | Composition pharmaceutique flottante comprenant une phase active et une phase non active |
| WO2001076592A1 (en) | 2000-04-06 | 2001-10-18 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neural regeneration |
| US6468559B1 (en) * | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
| GB0012209D0 (en) | 2000-05-19 | 2000-07-12 | Novartis Ag | Organic compounds |
| AU7410901A (en) | 2000-06-20 | 2002-01-02 | Novartis Ag | Method of administering bisphosphonates |
| US6476006B2 (en) | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
| CA2415052A1 (en) † | 2000-07-06 | 2002-01-17 | Wyeth | Combinations of bisphosphonates, estrogenic agents and optionally estrogens |
| EP1302201A4 (en) * | 2000-07-17 | 2007-09-05 | Astellas Pharma Inc | PHARMACEUTICAL COMPOSITION WITH IMPROVED ABSORBABILITY |
| US6638920B2 (en) | 2000-07-21 | 2003-10-28 | Merck & Co., Inc. | Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses |
| WO2002058708A1 (en) | 2001-01-23 | 2002-08-01 | Gador S.A. | Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof |
| AR034199A1 (es) | 2001-02-01 | 2004-02-04 | Riderway Corp | Composicion farmacologica liquida para el tratamiento de enfermedades oseas y procedimientos para su elaboracion |
| ATE496624T1 (de) | 2001-02-06 | 2011-02-15 | Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital | Arzneimittel zur behandlung von osteonekrose und zur versorgung von patienten mit risiko für die entstehung von osteonekrose |
| CN1492763B (zh) | 2001-03-01 | 2012-05-23 | 艾米斯菲尔技术有限公司 | 用于递送二膦酸盐的组合物 |
| US6692850B2 (en) * | 2001-03-07 | 2004-02-17 | Axsun Technologies, Inc. | Controlled stress optical coatings for membranes |
| CA2445922A1 (en) | 2001-05-10 | 2002-11-21 | Merck & Co., Inc. | Estrogen receptor modulators |
| WO2003051373A1 (en) | 2001-12-13 | 2003-06-26 | Merck & Co., Inc. | Liquid bisphosphonate formulations for bone disorders |
| RU2294203C2 (ru) | 2001-12-21 | 2007-02-27 | Дзе Проктер Энд Гэмбл Компани | Способ лечения костных нарушений |
| US20050070504A1 (en) | 2001-12-21 | 2005-03-31 | The Procter & Gamble Co. | Risedronate compositions and their methods of use |
| US7488496B2 (en) | 2002-03-06 | 2009-02-10 | Christer Rosen | Effervescent compositions comprising bisphosphonates and methods related thereto |
| WO2003086415A1 (en) | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
| KR100642961B1 (ko) † | 2002-05-10 | 2006-11-10 | 에프. 호프만-라 로슈 아게 | 골다공증 치료 및 예방용 비스포스폰산 |
-
2003
- 2003-08-07 PT PT70054630T patent/PT1790347E/pt unknown
- 2003-08-07 CN CN038098407A patent/CN1649598B/zh not_active Expired - Fee Related
- 2003-08-07 PL PL373655A patent/PL212072B1/pl unknown
- 2003-08-07 ES ES07005463T patent/ES2530791T3/es not_active Expired - Lifetime
- 2003-08-07 ES ES03813545T patent/ES2291749T5/es not_active Expired - Lifetime
- 2003-08-07 BR BR0309691-2A patent/BR0309691A/pt not_active Application Discontinuation
- 2003-08-07 JP JP2004561125A patent/JP4427453B2/ja not_active Expired - Lifetime
- 2003-08-07 NZ NZ536273A patent/NZ536273A/en not_active IP Right Cessation
- 2003-08-07 CA CA002484494A patent/CA2484494C/en not_active Expired - Fee Related
- 2003-08-07 PT PT03813545T patent/PT1596870E/pt unknown
- 2003-08-07 KR KR1020047017567A patent/KR100694550B1/ko active IP Right Grant
- 2003-08-07 SI SI200332409T patent/SI1790347T1/sl unknown
- 2003-08-07 MX MXPA04010866A patent/MXPA04010866A/es active IP Right Grant
- 2003-08-07 DE DE60315514T patent/DE60315514T3/de not_active Expired - Lifetime
- 2003-08-07 NZ NZ555514A patent/NZ555514A/en not_active IP Right Cessation
- 2003-08-07 RU RU2004132186/15A patent/RU2315603C2/ru not_active IP Right Cessation
- 2003-08-07 AU AU2003250218A patent/AU2003250218B2/en not_active Ceased
- 2003-08-07 AT AT03813545T patent/ATE369139T1/de active
- 2003-08-07 SI SI200330944T patent/SI1596870T2/sl unknown
- 2003-08-07 EP EP03813545A patent/EP1596870B2/en not_active Expired - Lifetime
- 2003-08-07 DK DK03813545.5T patent/DK1596870T4/da active
- 2003-08-07 EP EP07005463.0A patent/EP1790347B1/en not_active Expired - Lifetime
- 2003-08-07 WO PCT/EP2003/008732 patent/WO2004056373A1/en active Application Filing
- 2003-08-07 SG SG2007045750A patent/SG174628A1/en unknown
- 2003-08-07 DK DK07005463.0T patent/DK1790347T3/en active
- 2003-08-10 JO JO200394A patent/JO2663B1/en active
- 2003-08-12 US US10/639,010 patent/US7923028B2/en active Active
- 2003-08-14 PA PA20038580601A patent/PA8580601A1/es unknown
- 2003-08-15 PE PE2003000829A patent/PE20040416A1/es not_active Application Discontinuation
- 2003-08-15 TW TW092122526A patent/TWI342215B/zh not_active IP Right Cessation
- 2003-08-15 MY MYPI20033106A patent/MY143550A/en unknown
- 2003-08-15 UY UY27942A patent/UY27942A1/es not_active Application Discontinuation
- 2003-08-15 AR ARP030102961A patent/AR037560A1/es not_active Application Discontinuation
- 2003-08-16 EG EG2003080797A patent/EG26027A/en active
-
2004
- 2004-10-25 CR CR7549A patent/CR7549A/es unknown
- 2004-10-28 HR HRP20041013AA patent/HRP20041013B1/hr not_active IP Right Cessation
- 2004-10-29 EC EC2004005418A patent/ECSP045418A/es unknown
- 2004-11-01 ZA ZA2004/08822A patent/ZA200408822B/en unknown
- 2004-11-01 IL IL164956A patent/IL164956A/en active IP Right Grant
- 2004-11-01 NO NO20044722A patent/NO329690B1/no not_active IP Right Cessation
-
2006
- 2006-01-13 HK HK06100542.7A patent/HK1080714A1/xx not_active IP Right Cessation
-
2007
- 2007-03-02 AR ARP070100884A patent/AR059723A2/es not_active Application Discontinuation
- 2007-10-10 CY CY20071101303T patent/CY1107757T1/el unknown
-
2009
- 2009-09-10 IL IL200849A patent/IL200849A0/en unknown
-
2015
- 2015-03-16 CY CY20151100264T patent/CY1116123T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1117411B1 (en) | Process for the preparation of oral pharmaceutical compositions comprising biphosphonates | |
| NO329690B1 (no) | Tablett med hoy dose av ibandronat-formulering samt fremgangsmate for fremstilling av slike | |
| US6627221B2 (en) | Pharmaceutical composition containing diphosphonic acid or salt thereof | |
| AU2004275569B2 (en) | Pharmaceutical formulation with improved stability | |
| AU2006222690B2 (en) | High dose ibandronate formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |